Product details
Sermorelin is the unmodified 29-amino-acid N-terminal fragment of native human GHRH (residues 1-29), retaining the full receptor-binding activity of the parent 44-residue molecule. Approved historically as a prescription drug (Geref) for pediatric GH deficiency diagnosis, Sermorelin is the most studied GHRH-receptor agonist and serves as the reference compound against which engineered analogues (CJC-1295, Tesamorelin, Modified GRF 1-29) are compared. The molecule's clinical pharmacokinetic limitation, a serum half-life of roughly 10-12 minutes due to DPP-4 cleavage at the Tyr1-Ala2 bond, is the design problem that motivated the substitution chemistry behind the CJC-1295 family.
Peptuno supplies Sermorelin acetate as a lyophilized powder at ≥99.0% HPLC purity. The 29-residue sequence is within reliable SPPS range and the analytical packet covers peak-integration HPLC, ESI mass spec, water content, and counter-ion. Sermorelin is typically used in research contexts studying GHRH-receptor pharmacology at physiologically relevant time scales (the short half-life is a feature, not a bug, for pulse-pharmacology research) and in compounding workflows where the short-acting profile is appropriate. For sustained-action profiles, buyers generally route to CJC-1295 with DAC instead.
FAQ
- How does Sermorelin compare to CJC-1295 and Tesamorelin?
- All three are GHRH-receptor agonists, but they differ in their pharmacokinetic engineering. Sermorelin is the unmodified GHRH(1-29) fragment with a roughly 10-minute serum half-life, the native molecule's properties. CJC-1295 (no DAC) adds four amino-acid substitutions that resist DPP-4 cleavage, extending half-life to roughly 30 minutes while retaining the physiological pulsatile signaling pattern. Tesamorelin adds an N-terminal trans-3-hexenoyl group, similarly improving protease resistance and extending half-life, Tesamorelin is the only FDA-approved member of this family, indicated for HIV-associated lipodystrophy. CJC-1295 with DAC sits at the far end of the half-life spectrum at roughly a week via albumin binding.
- Why is Sermorelin's short half-life sometimes the preferred property?
- Research workflows studying GHRH-receptor pharmacology often need to characterize pulsatile signaling at physiologically relevant timescales, sustained-elevation models produce different downstream biology than pulse-pattern models because GH-release feedback loops respond to pulse architecture, not just average exposure. Sermorelin's short half-life makes it the cleanest tool for studying pulse-pharmacology, dose-response within a single GH pulse, and acute receptor pharmacology. For sustained-elevation research or for clinical contexts where convenience matters, the longer-acting CJC-1295 (no DAC) or CJC-1295 with DAC are preferred.
- Can Sermorelin be combined with a GHSR-pathway agonist like Ipamorelin?
- Yes, the GHRH-pathway plus GHSR-pathway combination strategy applies to Sermorelin the same way it applies to CJC-1295: combining a GHRH-receptor agonist with a GHSR agonist produces additive GH-release magnitudes beyond either component alone. The Sermorelin + Ipamorelin combination is less common than CJC-1295 + Ipamorelin in published research and compounding workflows simply because CJC-1295's longer half-life better matches Ipamorelin's, but for short-pulse research applications the Sermorelin combination is mechanistically equivalent.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.